Actively Recruiting
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Led by Aditya S. Pandey, MD · Updated on 2025-11-28
120
Participants Needed
1
Research Sites
288 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals. This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.
CONDITIONS
Official Title
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aneurysmal subarachnoid hemorrhage confirmed with vascular imaging
- Aneurysm treated with endovascular or microsurgical intervention
- Hunt-Hess score of 4 or less
- Modified Fisher Grade I to IV
- Glasgow Coma Scale score of 7 or higher after External Ventricular Drain placement if needed
- First dose of medication can be given within 24 hours of symptom onset
- Functional independence before the hemorrhage, with Modified Rankin Scale score of 1 or less
- Informed consent obtained from patient or legal authorized representative
You will not qualify if you...
- Previous hypersensitivity to or treatment with deferoxamine
- Presence of giant aneurysm larger than 25 mm
- Severe iron deficiency anemia (Hemoglobin 7 g/dL or less) or transfusion dependent
- Irreversibly impaired brainstem function
- Abnormal kidney function with serum creatinine over 2 mg/dL
- Pre-existing severe disability, Modified Rankin Scale score of 2 or higher
- Coagulopathy, including use of anti-platelet or anticoagulant drugs
- Known severe hearing loss
- Chronic lung disease limiting basic activities or requiring home oxygen
- Acute lung disease needing advanced oxygen support within 72 hours before enrollment
- Taking iron supplements with more than 325 mg of ferrous iron
- Pregnancy or nursing
- Life expectancy less than 90 days due to other health conditions
- Participation in another experimental therapy research trial (observational studies allowed)
- History of liver dysfunction
- Known low blood cell counts (platelets less than 50,000, neutrophils less than 500)
- Current use of prochlorperazine
- History of severe psychiatric disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
Research Team
S
Sravanthi Koduri
CONTACT
A
Aditya Pandey, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here